

# Leonid S Metelitsa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7008086/publications.pdf>

Version: 2024-02-01

31  
papers

3,304  
citations

236925

25  
h-index

454955

30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

3797  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells. <i>Journal of Immunology</i> , 2001, 167, 3114-3122.	0.8	315
2	V $\alpha$ 24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. <i>Journal of Clinical Investigation</i> , 2009, 119, 1524-1536.	8.2	287
3	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3525-3532.	1.6	236
4	Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. <i>Blood</i> , 2014, 124, 2824-2833.	1.4	229
5	Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2. <i>Journal of Experimental Medicine</i> , 2004, 199, 1213-1221.	8.5	215
6	Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. <i>Cancer Discovery</i> , 2017, 7, 1238-1247.	9.4	204
7	NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. <i>Cancer Immunology Research</i> , 2019, 7, 363-375.	3.4	180
8	Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. <i>Nature Medicine</i> , 2020, 26, 1686-1690.	30.7	159
9	Glycan-3 $\alpha$ -Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2020, 8, 309-320.	3.4	134
10	Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. <i>Clinical Cancer Research</i> , 2019, 25, 2915-2924.	7.0	129
11	CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. <i>Journal of Clinical Investigation</i> , 2016, 126, 2341-2355.	8.2	127
12	IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. <i>Journal of Clinical Investigation</i> , 2012, 122, 2221-2233.	8.2	126
13	NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced <i>In Vivo</i> Persistence and Antitumor Activity against Neuroblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 7126-7138.	7.0	112
14	Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. <i>Clinical Immunology</i> , 2011, 140, 119-129.	3.2	109
15	Distinct homeostatic requirements of CD4+ and CD4- subsets of V $\alpha$ 24-invariant natural killer T cells in humans. <i>Blood</i> , 2004, 104, 4150-4156.	1.4	97
16	Novel cancer vaccine based on genes of <i>Salmonella</i> pathogenicity island 2. <i>International Journal of Cancer</i> , 2010, 126, 2622-2634.	5.1	80
17	Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-Targeting <i>Salmonella</i> -Based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors. <i>Cancer Research</i> , 2011, 71, 4183-4191.	0.9	79
18	G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. <i>Cancer Research</i> , 2015, 75, 2566-2579.	0.9	78

#	ARTICLE	IF	CITATIONS
19	Antidisialoganglioside/granulocyte macrophage- colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on Fc $\gamma$ RII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. <i>Blood</i> , 2002, 99, 4166-4173.	1.4	74
20	Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. <i>Human Gene Therapy</i> , 2017, 28, 437-448.	2.7	72
21	Effective Cancer Vaccine Platform Based on Attenuated <i>Salmonella</i> and a Type III Secretion System. <i>Cancer Research</i> , 2014, 74, 6260-6270.	0.9	60
22	NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. <i>European Journal of Immunology</i> , 2002, 32, 3453-3462.	2.9	54
23	IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2018, 201, 2141-2153.	0.8	40
24	Evaluation of <i>Salmonella enterica</i> Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens. <i>Infection and Immunity</i> , 2012, 80, 1193-1202.	2.2	36
25	Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells. <i>Clinical Immunology</i> , 2004, 110, 267-276.	3.2	32
26	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. <i>Blood</i> , 2022, 140, 16-24.	1.4	14
27	A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor. <i>Cancer Immunology Research</i> , 2020, 8, 57-69.	3.4	11
28	A Nanoradiomics Approach for Differentiation of Tumors Based on Tumor-Associated Macrophage Burden. <i>Contrast Media and Molecular Imaging</i> , 2021, 2021, 1-9.	0.8	7
29	A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2647-TPS2647.	1.6	6
30	A new $\alpha$ -galactosylceramide analog: promotion of Th1-biased responses in human CD1d-reactive invariant natural killer T cells. <i>FASEB Journal</i> , 2007, 21, A605.	0.5	1
31	Glypican-3-specific CAR-NKT cells overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14521-e14521.	1.6	1